News
AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. Get access to the leaderboards pointing to tomorrow’s biggest stock movers.
Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...
Hosted on MSN4mon
Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing SolutionsOn January 8, AMD entered a strategic collaboration with Absci Corporation, including a $20 million investment to support the company’s AI-driven drug discovery efforts. By providing AMD ...
Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...
The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...
Absci is also collaborating with AMD to create hardware and software that will better cater to the healthcare sector and AI-based drug discovery. The company, which has approximately 160 employees and ...
Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results